Abstract
Diabetes caused a total annual cost of $548 billion worldwide in 2013 and accounted for 11% of total healthcare expenditures for adults. The aim of this study is to conduct a pharmacoeconomic evaluation of insulin glargine injection 300 Units/mL (IGI-300U/mL), used to treat type-1 and 2 diabetes (T1DM-T2DM), and compare its cost-minimization to that of its competitors in Turkiye.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
